Brokers Offer Predictions for Merus’ Q4 2020 Earnings (NASDAQ:MRUS) Posted by Denise Davis on Mar 19th, 2021
Merus (NASDAQ:MRUS) – Investment analysts at SVB Leerink issued their Q4 2020 earnings per share (EPS) estimates for shares of Merus in a research report issued on Tuesday, March 16th.SVB Leerink analyst A.Berens anticipates that the biotechnology company will post earnings of ($0.72) per share for the quarter.SVB Leerink has a “Outperform” rating and a $33.00 price objective on the stock.SVB Leerink also issued estimates for Merus’ Q1 2021 earnings at ($0.67) EPS, Q2 2021 earnings at ($0.65) EPS, Q3 2021 earnings at ($0.71) EPS, Q4 2021 earnings at ($0.76) EPS, FY2021 earnings at ($2.80) EPS, FY2022 earnings at ($2.95) EPS, FY2023 earnings at ($3.35) EPS, FY2024 earnings at ($4.59) EPS and FY2025 earnings at ($5.66) EPS.Get Merus alerts:
MRUS has been the topic of a number of other reports.HC Wainwright boosted their price target on shares of Merus from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday.
Roth Capital upped their price objective on Merus from $19.00 to $32.00 in a research note on Tuesday, January 19th.Royal Bank of Canada boosted their target price on Merus from $15.00 to $21.00 and gave the company a “sector perform” rating in a research note on Wednesday.Finally, Zacks Investment Research downgraded shares of Merus from a “hold” rating to a “sell” rating in a report on Friday, January 22nd.
One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock.The stock presently has an average rating of “Hold” and an average price target of $25.50.Shares of NASDAQ:MRUS opened at $21.99 on Thursday.Merus has a 1 year low of $10.18 and a 1 year high of $31.27.The company has a market capitalization of $694.95 million, a PE ratio of -7.16 and a beta of 0.83.
The business has a fifty day moving average price of $23.97 and a two-hundred day moving average price of $17.57.
Merus (NASDAQ:MRUS) last released its earnings results on Monday, March 15th.The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.53).Merus had a negative net margin of 295.98% and a negative return on equity of 78.70%.
In other Merus news, major shareholder Bvf Partners L.P/Il bought 844,680 shares of Merus stock in a transaction that occurred on Thursday, January 21st.The stock was acquired at an average cost of $24.75 per share, for a total transaction of $20,905,830.00.
The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link .Also, major shareholder Bvf Partners L.P/Il bought 250,000 shares of the firm’s stock in a transaction on Tuesday, March 16th.The stock was acquired at an average price of $23.00 per share, for a total transaction of $5,750,000.00.The disclosure for this purchase can be found here .
Corporate insiders own 7.40% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company.UBS Asset Management Americas Inc.purchased a new stake in Merus in the third quarter valued at approximately $142,000.Credit Suisse AG bought a new position in shares of Merus in the 4th quarter worth $186,000.State Street Corp raised its position in shares of Merus by 94.9% during the 3rd quarter.
State Street Corp now owns 26,268 shares of the biotechnology company’s stock valued at $315,000 after buying an additional 12,790 shares in the last quarter.Renaissance Technologies LLC bought a new stake in shares of Merus during the 4th quarter worth $435,000.
Finally, BlackRock Inc.grew its position in Merus by 3.5% in the third quarter.BlackRock Inc.now owns 74,391 shares of the biotechnology company’s stock worth $893,000 after acquiring an additional 2,534 shares in the last quarter.
62.57% of the stock is owned by institutional investors.
About Merus
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer.
Recommended Story: Cryptocurrencies Receive News & Ratings for Merus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merus and related companies with MarketBeat.com’s FREE daily email newsletter ..
